{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:56:39Z","timestamp":1784667399119,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ygyno.2021.12.022","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T16:13:03Z","timestamp":1640880783000},"page":"550-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis"],"prefix":"10.1016","volume":"164","author":[{"given":"Kelsey L.","family":"Corrigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Yoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Jhingran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Joyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Eifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Colbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Klopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ygyno.2021.12.022_bb0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.12.022_bb0010","series-title":"5-Year Relative Survival Rates, 2011\u20132017","author":"SEER","year":"2018"},{"issue":"2","key":"10.1016\/j.ygyno.2021.12.022_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/gyno.2000.5860","article-title":"Posttherapy surveillance of women with cervical cancer: an outcomes analysis","volume":"78","author":"Bodurka-Bevers","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.12.022_bb0020","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.12.022_bb0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","article-title":"Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a gynecologic oncology group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.12.022_bb0030","series-title":"Stereotactic Ablative Radiotherapy Versus Standard of Care Palliative Treatment in Patients with oliGometastatic Cancers (SABR-COMET): A Randomised, Phase 2, Open-Label Trial","first-page":"2051","volume":"393","author":"Palma","year":"2019"},{"issue":"2","key":"10.1016\/j.ygyno.2021.12.022_bb0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2020.08.010","article-title":"Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: a systematic review","volume":"159","author":"Yegya-Raman","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.022_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2017.10.017","article-title":"Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer","volume":"148","author":"Ning","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.022_bb0045","first-page":"E569","article-title":"Clinical outcomes of stereotactic body radiation therapy for extracranial oligometastatic ovarian cancer","volume":"105","author":"Mills","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.ygyno.2021.12.022_bb0050","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2021.12.022_bb0055","doi-asserted-by":"crossref","first-page":"S1247","DOI":"10.1245\/s10434-015-4604-2","article-title":"Single-institution multidisciplinary management of locoregional oligo-recurrent pelvic malignancies: long-term outcome analysis","volume":"22","author":"Sole","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"8\u20139","key":"10.1016\/j.ygyno.2021.12.022_bb0060","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/07357907.2020.1817483","article-title":"Stereotactic body radiation therapy in oligometastatic uterine cancer: clinical outcomes and toxicity","volume":"38","author":"Reddy","year":"2020","journal-title":"Cancer Investig."},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.022_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2018.12.049","article-title":"Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy","volume":"104","author":"Franceschini","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.ygyno.2021.12.022_bb0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/07357907.2015.1019678","article-title":"Stereotactic body radiotherapy for oligometastases confined to the Para-aortic region: clinical outcomes and the significance of radiotherapy field and dose","volume":"33","author":"Seo","year":"2015","journal-title":"Cancer Investig."},{"issue":"3","key":"10.1016\/j.ygyno.2021.12.022_bb0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2010.11.042","article-title":"Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology","volume":"120","author":"Higginson","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.12.022_bb0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ygyno.2020.10.001","article-title":"Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers","volume":"159","author":"Reshko","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.12.022_bb0085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2015.00126","article-title":"Phase I trial of carboplatin and gemcitabine chemotherapy and stereotactic ablative radiosurgery for the palliative treatment of persistent or recurrent gynecologic cancer","volume":"5","author":"Kunos","year":"2015","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2021.12.022_bb0090","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2021.12.022_bb0095","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2021.12.022_bb0100","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.12.022_bb0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ijgc-2020-001227","article-title":"Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin","volume":"30","author":"Lin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2021.12.022_bb0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-020-00748-6","article-title":"Stereotactic ablative radiotherapy for recurrent or metastatic gynecological cancer: extending lives?","volume":"21","author":"Zhang","year":"2020","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.ygyno.2021.12.022_bb0115","series-title":"Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer","author":"Fisher","year":"2017"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0120","series-title":"Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers","author":"Colbert","year":"2020"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0125","series-title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (MOMENTUM)","author":"Verkooijen","year":"2019"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0130","series-title":"MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer","author":"Robinson","year":"2015"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0135","series-title":"Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer","author":"Waggoner","year":"2012"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0140","series-title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","author":"Lee","year":"2017"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0145","series-title":"Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers","author":"Lin","year":"2018"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0150","series-title":"Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical\/Uterine Cancer (PRIMMO)","author":"Denys","year":"2017"},{"key":"10.1016\/j.ygyno.2021.12.022_bb0155","series-title":"SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer","author":"Ahmed","year":"2018"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821016905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821016905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:25Z","timestamp":1758772825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821016905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0090825821016905"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}